Strasbourg and Croissy-Beaubourg, December 15, 2023 – 6:00 p.m. CET – BIOSYNEX and THERADIAG announce that the extraordinary general meetings of shareholders of THERADIAG SA (Euronext Paris: ALTER) and BIOSYNEX SA (Euronext Paris: ALBIO) met today and approved the merger-absorption of THERADIAG by BIOSYNEX, on the basis of an exchange ratio of 1 BIOSYNEX share for 7 THERADIAG shares.
The Board of Directors of BIOSYNEX met after the extraordinary general meetings of the two companies and noted the completion of the operation. The merger-absorption leading to the dissolution without liquidation of THERADIAG took effect today, it being specified that it will, from an accounting and tax perspective, be retroactive to January 1, 2023.